Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plasmid AMEP
- Development stage
- Phase 1
- Lead developer
- Kaneka Eurogentec
- Modality
- Gene Therapies
- Administration
- Intratumoral, Intramuscular
01
Overview
Plasmid AMEP is a gene therapy agent encoding the protein antiangiogenic metargidin peptide (AMEP), which is the disintegrin domain of ADAM-15 (metargidin). It exerts antiproliferative and antiangiogenic effects by binding to αvγ3 and α5β1 integrins. The plasmid is designed without antibiotic resistance genes and is delivered to tissues using electrotransfer (electric pulses).
- Other names
- Antiangiogenic metargidin peptide
02
Targets
αVβ3 (Integrin αVβ3)ITGA5:ITGB1 (Integrin α5β1)
Beyond the preview
Go deeper on plasmid AMEP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plasmid AMEP.